NCT03090334

A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis

Terminated NA Last updated 28 August 2024

What this trial tests

NA trial testing De-escalation in Invasive Candidiases in 34 participants. Terminated before completion.

Timeline

1 March 2017

Primary endpoint
10 June 2019

10 June 2019

Quick facts

Lead sponsor	University of Bologna
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	34
Start date	1 March 2017
Primary completion	10 June 2019
Estimated completion	10 June 2019
Sites	1 location across Italy

Drugs / interventions tested

• De-escalation

Conditions studied

• Invasive Candidiases — all drugs for Invasive Candidiases →
• Abdominal Infection — all drugs for Abdominal Infection →

Sponsor

University of Bologna

Who can join

18 and older, any sex, with Invasive Candidiases or Abdominal Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be randomized (1:1) to:

1. discontinue antifungal treatment based on negative (\<80 pg/ml) result of 1,3 beta-d-glucan performed on day 0,3,6 and 10
2. continue antifungal treatment according with attending physician's decision.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.